FUNDING

Hassabis’ Isomorphic Labs Raises $5B Series C for AI Drugs

S Sarah Chen Nov 18, 2026 2 min read
Engine Score 9/10 — Critical

tier2 source, heuristic impact/novelty scan

Editorial illustration for: Hassabis' Isomorphic Labs Raises $5B Series C for AI Drugs
  • Isomorphic Labs, the AI drug-discovery company founded by former Google DeepMind CEO Demis Hassabis, raised a $5 billion Series C round announced November 17, 2026.
  • The round was co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and continued investment from Alphabet.
  • The raise comes three and a half months after Hassabis stepped back as CEO of Google DeepMind.
  • Isomorphic last raised $2.1 billion in a Series B round in May 2026.

What Happened

Isomorphic Labs, the AI drug-discovery company Demis Hassabis founded alongside his role at Google DeepMind, raised a $5 billion Series C round announced November 17, 2026, CNBC reported. Greenoaks and Sequoia Capital co-led the round, with Andreessen Horowitz joining as a new investor and Alphabet continuing to invest.

Why It Matters

The raise lands three and a half months after Hassabis stepped back as CEO of Google DeepMind, underscoring that investors are betting on Isomorphic’s AI-drug-design approach independent of his DeepMind role. The company had already moved toward its first human drug trials earlier in 2026, giving the new funding a concrete near-term use.

Technical Details

Isomorphic says the new capital will accelerate its programs toward clinical trials. The company’s disclosed funding has grown quickly: it raised $2.1 billion in a Series B round in May 2026, and the $5 billion Series C more than doubles that figure in a single round six months later.

Who’s Affected

The raise affects Isomorphic’s drug-discovery pipeline partners and the broader AI-for-biotech sector, where large late-stage checks have concentrated in a small number of companies. Alphabet’s continued participation also ties Google’s balance sheet more closely to an AI-drug-design bet that sits outside Google DeepMind itself.

What’s Next

Isomorphic has not disclosed a specific valuation for the Series C or named which drug programs will be prioritized for the accelerated clinical-trial timeline. Its next disclosed milestone will likely be progress updates on the human trials it had already begun moving toward earlier this year.

Share

Enjoyed this story?

Get articles like this delivered daily. The Engine Room — free AI intelligence newsletter.

Free · No spam · Unsubscribe anytime